Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD039
MIFTS: 32

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Adenocarcinoma

About this section

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 70
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 54

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3711
NCIt 50 C4032
SNOMED-CT 67 255110003
UMLS 70 C0279682
Sources

Summaries for Bladder Adenocarcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to bladder clear cell adenocarcinoma and mammary paget's disease, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1). The drugs Methotrexate and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate, skin and lymph node.

Sources

Related Diseases for Bladder Adenocarcinoma

About this section

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 bladder clear cell adenocarcinoma 30.2 UPK3A NAPSA KRT7 KRT20 CDX2 AMACR
2 mammary paget's disease 30.2 KRT7 KRT20 ERBB2
3 appendix adenocarcinoma 30.1 KRT7 KRT20 CDX2
4 cystitis 30.0 UPK3A KRT7 KRT20
5 papilloma 30.0 PCNA KRT7 KRT20 ERBB2
6 inverted papilloma 30.0 PCNA MKI67 KRT7 KRT20
7 linitis plastica 29.9 KRT7 KRT20 ERBB2 CDX2
8 adenocarcinoma in situ 29.8 KRT7 KRT20 CDX2
9 colorectal adenocarcinoma 29.7 KRT7 KRT20 ERBB2 CDX2
10 bladder cancer 29.7 UPK3A UCA1 MKI67 KRT20 ERBB2
11 clear cell adenocarcinoma 29.6 NAPSA KRT7 KRT20 KLK3 AMACR
12 adenoma 29.6 MKI67 KRT7 KRT20 CDX2
13 cystitis cystica 29.6 KRT7 KRT20 KLK3 CDX2
14 signet ring cell adenocarcinoma 29.5 KRT7 KRT20 ERBB2 CDX2
15 rectum adenocarcinoma 29.5 KRT7 KRT20 ERBB2 CDX2
16 suppression of tumorigenicity 12 29.5 KLK3 ERBB2 AMACR
17 villous adenoma 29.5 KRT7 KRT20 KLK3 CDX2
18 adenocarcinoma 29.5 NAPSA KRT7 KRT20 KLK3 ERBB2 CDX2
19 mucinous adenocarcinoma 29.4 KRT7 KRT20 ERBB2 CDX2 AMACR
20 endometrial cancer 29.1 UCA1 PCNA MKI67 KRT7 KRT20 KLK3
21 nephrogenic adenoma 28.9 NAPSA KRT7 KLK3 AMACR
22 lung cancer susceptibility 3 28.8 NAPSA KRT7 KRT20 ERBB2 CDX2
23 glandular cystitis 28.8 UPK3A UCA1 KRT7 KRT20 CDX2 AMACR
24 transitional cell carcinoma 28.8 UPK3A MKI67 KRT7 KRT20 KLK3 ERBB2
25 pelvic lipomatosis 11.2
26 bladder signet ring cell adenocarcinoma 11.1
27 hepatoid adenocarcinoma 10.3
28 her2-receptor positive breast cancer 10.3 UCA1 ERBB2
29 intracranial meningioma 10.3 PCNA MKI67
30 oncocytic breast carcinoma 10.3 KRT7 ERBB2
31 oral leukoplakia 10.3 PCNA MKI67
32 leukoplakia 10.3 PCNA MKI67
33 necrotizing sialometaplasia 10.3 MKI67 KRT7
34 breast metaplastic carcinoma 10.3 KRT7 ERBB2
35 breast mucinous carcinoma 10.3 KRT7 ERBB2
36 ovary neuroendocrine neoplasm 10.3 KRT7 CDX2
37 hydronephrosis 10.3
38 anal canal paget's disease 10.3 KRT7 CDX2
39 anal paget's disease 10.3 KRT7 CDX2
40 gastric signet ring cell adenocarcinoma 10.3 KRT7 CDX2
41 anal gland adenocarcinoma 10.3 KRT7 CDX2
42 ureter adenocarcinoma 10.3 KRT7 CDX2
43 anus adenocarcinoma 10.3 KRT7 CDX2
44 mucinous adenofibroma 10.3 KRT7 CDX2
45 pancreatic foamy gland adenocarcinoma 10.3 KRT7 CDX2
46 adenosquamous colon carcinoma 10.3 KRT7 CDX2
47 mixed fibrolamellar hepatocellular carcinoma 10.3 KRT7 ERBB2
48 ethmoid sinus adenocarcinoma 10.3 ERBB2 CDX2
49 apocrine sweat gland neoplasm 10.3 KRT7 ERBB2
50 mucinous intrahepatic cholangiocarcinoma 10.3 KRT7 CDX2

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma
Sources

Symptoms & Phenotypes for Bladder Adenocarcinoma

About this section

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria
Sources

Drugs & Therapeutics for Bladder Adenocarcinoma

About this section

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
2
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
3
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
4
Daunorubicin Approved Phase 2 20830-81-3 30323
5
Gemcitabine Approved Phase 2 95058-81-4 60750
6
Vinblastine Approved Phase 2 865-21-4 241903 13342
7
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
8
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
9
Durvalumab Approved, Investigational Phase 2 1428935-60-7
10
Ipilimumab Approved Phase 2 477202-00-9
11
nivolumab Approved Phase 2 946414-94-4
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
13 Anti-Infective Agents Phase 2
14 Immunologic Factors Phase 2
15 Anti-Bacterial Agents Phase 2
16 Vitamin B9 Phase 2
17 Folic Acid Antagonists Phase 2
18 Tubulin Modulators Phase 2
19 Antibiotics, Antitubercular Phase 2
20
Liposomal doxorubicin Phase 2 31703
21 Antimitotic Agents Phase 2
22 Antineoplastic Agents, Immunological Phase 2
23 Antirheumatic Agents Phase 2
24 Immunosuppressive Agents Phase 2
25 Dermatologic Agents Phase 2
26 Vitamin B Complex Phase 2
27 Folate Phase 2
28 Antiviral Agents Phase 2
29 Antimetabolites Phase 2
30 Immunoglobulins Phase 2
31 Antibodies, Monoclonal Phase 2
32 Antibodies Phase 2
33
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
34
Metronidazole Approved Phase 1 443-48-1 4173
35
Molgramostim Investigational Phase 1 99283-10-0
36 Antiparasitic Agents Phase 1
37 Antiprotozoal Agents Phase 1
38 Vaccines Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
2 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
3 Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Sources

Genetic Tests for Bladder Adenocarcinoma

About this section
Sources

Anatomical Context for Bladder Adenocarcinoma

About this section

MalaCards organs/tissues related to Bladder Adenocarcinoma:

40
Prostate, Skin, Lymph Node, Colon, Uterus
Sources

Publications for Bladder Adenocarcinoma

About this section

Articles related to Bladder Adenocarcinoma:

(show top 50) (show all 158)
# Title Authors PMID Year
1
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. 54 61
18789486 2009
2
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 61 54
18670358 2008
3
[Expression of CDX2 in urinary bladder and urethra lesions]. 54 61
15074058 2004
4
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. 54 61
11684954 2001
5
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 54 61
10658909 2000
6
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. 61 54
9522212 1998
7
Difficult cystoscopy due to "Elongated" urethra- think of pelvic lipomatosis. 61
33251114 2021
8
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma. 61
31876604 2020
9
A rare case of esophageal adenocarcinoma with urinary bladder metastasis. 61
32904040 2020
10
Secondary tumors of the bladder: A survival outcome study. 61
32836180 2020
11
Comparative genomic profiling of glandular bladder tumours. 61
32198650 2020
12
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. 61
32520749 2020
13
Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis. 61
32850200 2020
14
Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. 61
31740332 2020
15
HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target. 61
32317518 2020
16
Coexistent Dedifferentiated Endometrioid Carcinoma of the Uterus and Adenocarcinoma of the Bladder in Lynch Syndrome: Case Report and Review of the Literature. 61
32167968 2020
17
Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. 61
31496327 2020
18
Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring HER2 Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report. 61
32547059 2020
19
Bile spillage and incidental gall bladder adenocarcinoma. 61
31929997 2019
20
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. 61
31666198 2019
21
Aggressive course in a patient with mucin-producing urothelial-type adenocarcinoma of the prostate: A case report and review of the literature. 61
32027595 2019
22
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 61
31395362 2019
23
A report of orbital metastasis from a urinary bladder adenocarcinoma. 61
31332150 2019
24
Mimickers of urothelial neoplasia. 61
30380401 2019
25
Case Report: Bladder adenocarcinoma: primary or urachal? 61
32832071 2019
26
Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. 61
31317053 2019
27
Primary signet-ring cell carcinoma of the urinary bladder: A report of two cases. 61
31535712 2019
28
Non-urothelial carcinomas of the bladder. 61
30565306 2019
29
Treating bladder adenocarcinoma. 61
30687599 2018
30
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 61
31049173 2018
31
microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. 61
29693148 2018
32
Primary bladder adenocarcinoma: Case report with long-term follow-up. 61
29785373 2018
33
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. 61
27048257 2018
34
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. 61
29203990 2017
35
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. 61
28548125 2017
36
Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features - multiple primaries versus metastatic neoplasms: a case report. 61
28494807 2017
37
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. 61
28511402 2017
38
Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. 61
28056456 2017
39
Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. 61
32913973 2017
40
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. 61
27381065 2016
41
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. 61
27427223 2016
42
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. 61
27703678 2016
43
Cutaneous metastasis: An unusual presenting feature of urologic malignancies. 61
27453667 2016
44
Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. 61
27267922 2016
45
[Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review]. 61
27266688 2016
46
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. 61
26463756 2016
47
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. 61
27081650 2016
48
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. 61
26955660 2016
49
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. 61
27006847 2016
50
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. 61
27288750 2016
Sources

Variations for Bladder Adenocarcinoma

About this section
Sources

Expression for Bladder Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bladder Adenocarcinoma.
Sources

Pathways for Bladder Adenocarcinoma

About this section
Sources

GO Terms for Bladder Adenocarcinoma

About this section

Molecular functions related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 8.8 PCNA MKI67 ERBB2
Sources

Sources for Bladder Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....